JieYee personal page - To The Moon

JieYee

JieYee

No personal profile

26Follow

5Followers

0Topic

0Badge

2021-08-29

Very interesting, great and useful article to all thereaders. Good job

Crypto stocks surged in morning trading

2021-08-29

very great and useful article for all buyers

U.S. resumes supply of Lilly's COVID-19 antibody combo to some states

2021-08-29

hi

Got $1,000? Buy This Hot Stock That Jumped 10X and Could Do It Again

2021-08-26

hi

Here's Why You Should Stay Away From Coinbase Stock

2021-08-26

hi

Johnson & Johnson Announces Data to Support Boosting its Single-Shot COVID-19 Vaccine

2021-08-26

[Strong]

Sorry, the original content has been removed

2021-08-23

hi

Sorry, the original content has been removed

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3585337577037707","uuid":"3585337577037707","gmtCreate":1622302097917,"gmtModify":1629729158976,"name":"JieYee","pinyin":"jieyee","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/3e4b8be34071a883cb274790cad527e5","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":5,"headSize":26,"tweetSize":7,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-1","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Debut Tiger","description":"Join the tiger community for 500 days","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.12.06","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":813640359,"gmtCreate":1630200876071,"gmtModify":1676530241267,"author":{"id":"3585337577037707","authorId":"3585337577037707","name":"JieYee","avatar":"https://static.tigerbbs.com/3e4b8be34071a883cb274790cad527e5","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585337577037707","authorIdStr":"3585337577037707"},"themes":[],"htmlText":"Very interesting, great and useful article to all thereaders. Good job&nbsp;","listText":"Very interesting, great and useful article to all thereaders. Good job&nbsp;","text":"Very interesting, great and useful article to all thereaders. Good job","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/813640359","repostId":"1199074003","repostType":4,"repost":{"id":"1199074003","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1630077382,"share":"https://ttm.financial/m/news/1199074003?lang=&edition=fundamental","pubTime":"2021-08-27 23:16","market":"us","language":"en","title":"Crypto stocks surged in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1199074003","media":"Tiger Newspress","summary":"Crypto stocks surged in morning trading.Bit Digital,Marathon Digital,Riot Blockchain,SoS Ltd,Square,","content":"<p>Crypto stocks surged in morning trading.Bit Digital,Marathon Digital,Riot Blockchain,SoS Ltd,Square,Coinbase&nbsp;and&nbsp;Paypal&nbsp;climbed between 1% and 13%.</p>\n<p><img src=\"https://static.tigerbbs.com/67735af69f95f6a88ee67ae3737e58c0\" tg-width=\"364\" tg-height=\"715\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Crypto stocks surged in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCrypto stocks surged in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-27 23:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Crypto stocks surged in morning trading.Bit Digital,Marathon Digital,Riot Blockchain,SoS Ltd,Square,Coinbase&nbsp;and&nbsp;Paypal&nbsp;climbed between 1% and 13%.</p>\n<p><img src=\"https://static.tigerbbs.com/67735af69f95f6a88ee67ae3737e58c0\" tg-width=\"364\" tg-height=\"715\" width=\"100%\" height=\"auto\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MARA":"Marathon Digital Holdings Inc","SOS":"SOS Limited","EBON":"亿邦国际","NCTY":"第九城市","SQ":"Block","RIOT":"Riot Platforms","BTCM":"BIT Mining","COIN":"Coinbase Global, Inc.","BTBT":"Bit Digital, Inc.","CAN":"嘉楠科技"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199074003","content_text":"Crypto stocks surged in morning trading.Bit Digital,Marathon Digital,Riot Blockchain,SoS Ltd,Square,Coinbase and Paypal climbed between 1% and 13%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":529,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":813657386,"gmtCreate":1630200820645,"gmtModify":1676530241250,"author":{"id":"3585337577037707","authorId":"3585337577037707","name":"JieYee","avatar":"https://static.tigerbbs.com/3e4b8be34071a883cb274790cad527e5","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585337577037707","authorIdStr":"3585337577037707"},"themes":[],"htmlText":"very great and useful article for all buyers&nbsp;","listText":"very great and useful article for all buyers&nbsp;","text":"very great and useful article for all buyers","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/813657386","repostId":"2162707824","repostType":4,"repost":{"id":"2162707824","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1630104635,"share":"https://ttm.financial/m/news/2162707824?lang=&edition=fundamental","pubTime":"2021-08-28 06:50","market":"us","language":"en","title":"U.S. resumes supply of Lilly's COVID-19 antibody combo to some states","url":"https://stock-news.laohu8.com/highlight/detail?id=2162707824","media":"Reuters","summary":"Aug 27 (Reuters) - U.S. health officials on Friday decided to resume the supply of Eli Lilly's COVID","content":"<p>Aug 27 (Reuters) - U.S. health officials on Friday decided to resume the supply of Eli Lilly's COVID-19 antibody cocktail to states where variants resistant to it are low, saying the therapy could work against the fast-spreading Delta variant based on lab studies.</p>\n<p>The Department of Health and Human Services narrowed the scope of authorization for the dual-antibody therapy, bamlanivimab and etesevimab, to states including Colorado, Connecticut and Illinois, Indiana.</p>\n<p>With the Delta variant becoming the dominant strain, the prevalence of variants resistant to the therapy is steadily decreasing, the agency said</p>\n<p>Based on lab tests, the drugs administered together are expected to retain activity against the Delta variant, but not against Delta plus and variants first identified in Brazil, South Africa and Colombia, it said.</p>\n<p>The department had in June paused its distribution after the therapy failed to show effectiveness against the coronavirus variants that were first identified in Brazil and South Africa.</p>\n<p>The supply of standalone etesevimab to be paired with existing supply of bamlanivimab is also being resumed to some states.</p>\n<p>Regeneron's antibody therapy REGEN-COV, and GlaxoSmithKline Plc and partner Vir Biotechnology's</p>\n<p>sotrovimab may be used in all states, territories, and U.S. jurisdictions as they are likely to be effective against most variants including Delta, the agency said.</p>\n<p>Bamlanivimab and etesevimab, REGEN-COV and sotrovimab are authorized for use in people 12 years and above with mild-to-moderate infection and are at high risk for progression to severe COVID-19.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. resumes supply of Lilly's COVID-19 antibody combo to some states</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. resumes supply of Lilly's COVID-19 antibody combo to some states\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-08-28 06:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Aug 27 (Reuters) - U.S. health officials on Friday decided to resume the supply of Eli Lilly's COVID-19 antibody cocktail to states where variants resistant to it are low, saying the therapy could work against the fast-spreading Delta variant based on lab studies.</p>\n<p>The Department of Health and Human Services narrowed the scope of authorization for the dual-antibody therapy, bamlanivimab and etesevimab, to states including Colorado, Connecticut and Illinois, Indiana.</p>\n<p>With the Delta variant becoming the dominant strain, the prevalence of variants resistant to the therapy is steadily decreasing, the agency said</p>\n<p>Based on lab tests, the drugs administered together are expected to retain activity against the Delta variant, but not against Delta plus and variants first identified in Brazil, South Africa and Colombia, it said.</p>\n<p>The department had in June paused its distribution after the therapy failed to show effectiveness against the coronavirus variants that were first identified in Brazil and South Africa.</p>\n<p>The supply of standalone etesevimab to be paired with existing supply of bamlanivimab is also being resumed to some states.</p>\n<p>Regeneron's antibody therapy REGEN-COV, and GlaxoSmithKline Plc and partner Vir Biotechnology's</p>\n<p>sotrovimab may be used in all states, territories, and U.S. jurisdictions as they are likely to be effective against most variants including Delta, the agency said.</p>\n<p>Bamlanivimab and etesevimab, REGEN-COV and sotrovimab are authorized for use in people 12 years and above with mild-to-moderate infection and are at high risk for progression to severe COVID-19.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VIR":"Vir Biotechnology, Inc.","LLY":"礼来","REGN":"再生元制药公司"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2162707824","content_text":"Aug 27 (Reuters) - U.S. health officials on Friday decided to resume the supply of Eli Lilly's COVID-19 antibody cocktail to states where variants resistant to it are low, saying the therapy could work against the fast-spreading Delta variant based on lab studies.\nThe Department of Health and Human Services narrowed the scope of authorization for the dual-antibody therapy, bamlanivimab and etesevimab, to states including Colorado, Connecticut and Illinois, Indiana.\nWith the Delta variant becoming the dominant strain, the prevalence of variants resistant to the therapy is steadily decreasing, the agency said\nBased on lab tests, the drugs administered together are expected to retain activity against the Delta variant, but not against Delta plus and variants first identified in Brazil, South Africa and Colombia, it said.\nThe department had in June paused its distribution after the therapy failed to show effectiveness against the coronavirus variants that were first identified in Brazil and South Africa.\nThe supply of standalone etesevimab to be paired with existing supply of bamlanivimab is also being resumed to some states.\nRegeneron's antibody therapy REGEN-COV, and GlaxoSmithKline Plc and partner Vir Biotechnology's\nsotrovimab may be used in all states, territories, and U.S. jurisdictions as they are likely to be effective against most variants including Delta, the agency said.\nBamlanivimab and etesevimab, REGEN-COV and sotrovimab are authorized for use in people 12 years and above with mild-to-moderate infection and are at high risk for progression to severe COVID-19.","news_type":1},"isVote":1,"tweetType":1,"viewCount":501,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":813654346,"gmtCreate":1630200746485,"gmtModify":1676530241235,"author":{"id":"3585337577037707","authorId":"3585337577037707","name":"JieYee","avatar":"https://static.tigerbbs.com/3e4b8be34071a883cb274790cad527e5","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585337577037707","authorIdStr":"3585337577037707"},"themes":[],"htmlText":"hi","listText":"hi","text":"hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/813654346","repostId":"2162024053","repostType":4,"repost":{"id":"2162024053","pubTimestamp":1630110600,"share":"https://ttm.financial/m/news/2162024053?lang=&edition=fundamental","pubTime":"2021-08-28 08:30","market":"us","language":"en","title":"Got $1,000? Buy This Hot Stock That Jumped 10X and Could Do It Again","url":"https://stock-news.laohu8.com/highlight/detail?id=2162024053","media":"Motley Fool","summary":"A stronger pace of growth in the future, thanks to solid demand, could send this tech stock's price much higher.","content":"<p><b>Applied Materials</b> (NASDAQ:AMAT) looked like an enticing bet going into its fiscal 2021 third-quarter earnings report, and the company didn't disappoint as it crushed Wall Street's expectations on the back of terrific growth in revenue and earnings. What's more, Applied's guidance turned out to be strong as well, fueled by the massive growth in semiconductor investments across the globe as chipmakers are scrambling to meet huge end-market demand.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/36e7c524b510f3ddf875d48fa2f3ac29\" tg-width=\"700\" tg-height=\"393\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<p>It's worth noting that Applied Materials stock is now trading at a cheaper valuation than it was before the quarterly report came out, thanks to the terrific earnings growth. Its price-to-earnings (P/E) ratio is just 23, while the forward earnings multiple of 17 indicates that more bottom-line growth is in the cards. These multiples are lower than the <b>S&amp;P 500 Index</b>'s trailing P/E of 31 and forward P/E of 22.</p>\n<p>That means there's a golden opportunity for investors to add a rapidly growing company to their portfolios at an attractive valuation, and they shouldn't miss out. Let's look at some reasons.</p>\n<h2>Applied Materials is now growing at a blistering pace</h2>\n<p>A $1,000 investment in Applied Materials stock a decade ago would be worth almost $12,000 now:</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/81e0104d17e81fcbfbe06af299b88f05\" tg-width=\"720\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>AMAT data by YCharts.</span></p>\n<p>However, as the chart above shows, the company's top and bottom lines haven't exactly grown at a blistering pace over the past 10 years. Its revenue just about doubled, while earnings growth hasn't been eye-popping either, considering the pace at which the broader market's bottom line has increased. Also, as the chart indicates, most of Applied Materials' gains arrived in the past year and a half, after it became evident that the company's offerings would remain in hot demand amid a global semiconductor shortage that has disrupted several industries.</p>\n<p>Not surprisingly, Applied Materials' revenue and earnings have been growing at a much faster pace when compared to its average annual growth in the past 10 years. The company delivered record quarterly revenue of $6.2 billion in Q3, up 41% year over year. It also clocked a record (adjusted) operating margin of 32.7%, a jump of 6.3 percentage points over the prior year.</p>\n<p>The terrific sales and margin growth led to record adjusted earnings of $1.90 per share, up 79% from the year-ago quarter. The results crushed the expectations of analysts who'd been looking for $1.77 per share in earnings on $5.94 billion in revenue.</p>\n<p>Applied Materials' guidance was the icing on the cake. The company expects, at the midpoint of its guidance range, to earn $1.94 per share this quarter on revenue of $6.33 billion. Wall Street had set the bar lower; analysts were expecting just $1.81 in earnings per share on $6.04 billion in revenue. The midpoint of the guidance indicates that Applied is anticipating 35% year-over-year revenue growth this quarter, while non-GAAP (adjusted) earnings could increase 55%.</p>\n<p>The impressive guidance is a clue that Applied Materials has switched into a higher gear, and it's unlikely to step off the gas given the massive end-market opportunity at hand. In fact, it wouldn't be surprising to see its growth over the next decade significantly outpacing the rate at which it's grown in the past 10 years, helping the stock to fly higher once again.</p>\n<h2>Sustainable growth drivers can help the stock soar</h2>\n<p>Applied Materials supplies chip fabrication equipment, services, and software to semiconductor manufacturers. Its largest source of revenue is the semiconductor systems business, through which Applied develops, manufactures, and sells semiconductor fabrication equipment. This segment produced nearly 72% of the company's total revenue last quarter and recorded 53% year-over-year growth.</p>\n<p>Within the semiconductor systems business, the foundry/logic vertical occupied the largest share with 63% of total revenue, up from 55% in the year-ago quarter. The foundry business is built for long-term growth, as chipmakers across the globe are ramping up capacity. For instance, global semiconductor capital spending stood at an estimated $29.4 billion in 2010, according to <b>Gartner</b>. Last year, that number had ballooned to $106.9 billion.</p>\n<p>Gartner estimates that global semiconductor spending will rise to $141.9 billion this year. Spending on semiconductor equipment can keep moving higher in the coming years on the back of a huge jump in chip demand.</p>\n<p>Applied Materials points out that the semiconductor industry took 40 years to achieve its first $200 billion in revenue; from 2000 to 2017, the industry added the next $200 billion. An additional $200 billion of revenue is expected by 2024, over a shorter span of just seven years. What's more, the semiconductor industry's revenue is anticipated to increase a whopping $400 billion from 2025 to 2030, hitting $1 trillion at the end of the forecast period.</p>\n<p>Chipmakers will need to buy new equipment or upgrade their existing setups to cater to this massive increase in semiconductor demand, which will be driven by several verticals including automotive, networking, and industrial. Discussing \"PPACt\" (chip power efficiency, performance, area, cost, and time to market), Applied Materials CEO Gary Dickerson said on the Q3 earnings call that the company is on track to take advantage of these tailwinds and outperform the broader market:</p>\n<blockquote>\n As we look ahead, we are confident that the strength of longer-term secular trends will drive semiconductor and wafer fab equipment markets structurally higher. And we believe Applied is in the best position to accelerate our customers' PPACt roadmaps, and grow significantly faster than our markets.\n</blockquote>\n<p>All of this indicates that Applied Materials is in a solid position to deliver more upside. Analysts expect the company's earnings to clock a compound annual growth rate (CAGR) of nearly 25% for the next five years. At its current valuation, buying this tech stock is a no-brainer.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Got $1,000? Buy This Hot Stock That Jumped 10X and Could Do It Again</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGot $1,000? Buy This Hot Stock That Jumped 10X and Could Do It Again\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-28 08:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/27/got-1000-buy-this-hot-stock-that-could-jump-10x-on/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Applied Materials (NASDAQ:AMAT) looked like an enticing bet going into its fiscal 2021 third-quarter earnings report, and the company didn't disappoint as it crushed Wall Street's expectations on the ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/27/got-1000-buy-this-hot-stock-that-could-jump-10x-on/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMAT":"应用材料"},"source_url":"https://www.fool.com/investing/2021/08/27/got-1000-buy-this-hot-stock-that-could-jump-10x-on/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2162024053","content_text":"Applied Materials (NASDAQ:AMAT) looked like an enticing bet going into its fiscal 2021 third-quarter earnings report, and the company didn't disappoint as it crushed Wall Street's expectations on the back of terrific growth in revenue and earnings. What's more, Applied's guidance turned out to be strong as well, fueled by the massive growth in semiconductor investments across the globe as chipmakers are scrambling to meet huge end-market demand.\nImage source: Getty Images.\nIt's worth noting that Applied Materials stock is now trading at a cheaper valuation than it was before the quarterly report came out, thanks to the terrific earnings growth. Its price-to-earnings (P/E) ratio is just 23, while the forward earnings multiple of 17 indicates that more bottom-line growth is in the cards. These multiples are lower than the S&P 500 Index's trailing P/E of 31 and forward P/E of 22.\nThat means there's a golden opportunity for investors to add a rapidly growing company to their portfolios at an attractive valuation, and they shouldn't miss out. Let's look at some reasons.\nApplied Materials is now growing at a blistering pace\nA $1,000 investment in Applied Materials stock a decade ago would be worth almost $12,000 now:\nAMAT data by YCharts.\nHowever, as the chart above shows, the company's top and bottom lines haven't exactly grown at a blistering pace over the past 10 years. Its revenue just about doubled, while earnings growth hasn't been eye-popping either, considering the pace at which the broader market's bottom line has increased. Also, as the chart indicates, most of Applied Materials' gains arrived in the past year and a half, after it became evident that the company's offerings would remain in hot demand amid a global semiconductor shortage that has disrupted several industries.\nNot surprisingly, Applied Materials' revenue and earnings have been growing at a much faster pace when compared to its average annual growth in the past 10 years. The company delivered record quarterly revenue of $6.2 billion in Q3, up 41% year over year. It also clocked a record (adjusted) operating margin of 32.7%, a jump of 6.3 percentage points over the prior year.\nThe terrific sales and margin growth led to record adjusted earnings of $1.90 per share, up 79% from the year-ago quarter. The results crushed the expectations of analysts who'd been looking for $1.77 per share in earnings on $5.94 billion in revenue.\nApplied Materials' guidance was the icing on the cake. The company expects, at the midpoint of its guidance range, to earn $1.94 per share this quarter on revenue of $6.33 billion. Wall Street had set the bar lower; analysts were expecting just $1.81 in earnings per share on $6.04 billion in revenue. The midpoint of the guidance indicates that Applied is anticipating 35% year-over-year revenue growth this quarter, while non-GAAP (adjusted) earnings could increase 55%.\nThe impressive guidance is a clue that Applied Materials has switched into a higher gear, and it's unlikely to step off the gas given the massive end-market opportunity at hand. In fact, it wouldn't be surprising to see its growth over the next decade significantly outpacing the rate at which it's grown in the past 10 years, helping the stock to fly higher once again.\nSustainable growth drivers can help the stock soar\nApplied Materials supplies chip fabrication equipment, services, and software to semiconductor manufacturers. Its largest source of revenue is the semiconductor systems business, through which Applied develops, manufactures, and sells semiconductor fabrication equipment. This segment produced nearly 72% of the company's total revenue last quarter and recorded 53% year-over-year growth.\nWithin the semiconductor systems business, the foundry/logic vertical occupied the largest share with 63% of total revenue, up from 55% in the year-ago quarter. The foundry business is built for long-term growth, as chipmakers across the globe are ramping up capacity. For instance, global semiconductor capital spending stood at an estimated $29.4 billion in 2010, according to Gartner. Last year, that number had ballooned to $106.9 billion.\nGartner estimates that global semiconductor spending will rise to $141.9 billion this year. Spending on semiconductor equipment can keep moving higher in the coming years on the back of a huge jump in chip demand.\nApplied Materials points out that the semiconductor industry took 40 years to achieve its first $200 billion in revenue; from 2000 to 2017, the industry added the next $200 billion. An additional $200 billion of revenue is expected by 2024, over a shorter span of just seven years. What's more, the semiconductor industry's revenue is anticipated to increase a whopping $400 billion from 2025 to 2030, hitting $1 trillion at the end of the forecast period.\nChipmakers will need to buy new equipment or upgrade their existing setups to cater to this massive increase in semiconductor demand, which will be driven by several verticals including automotive, networking, and industrial. Discussing \"PPACt\" (chip power efficiency, performance, area, cost, and time to market), Applied Materials CEO Gary Dickerson said on the Q3 earnings call that the company is on track to take advantage of these tailwinds and outperform the broader market:\n\n As we look ahead, we are confident that the strength of longer-term secular trends will drive semiconductor and wafer fab equipment markets structurally higher. And we believe Applied is in the best position to accelerate our customers' PPACt roadmaps, and grow significantly faster than our markets.\n\nAll of this indicates that Applied Materials is in a solid position to deliver more upside. Analysts expect the company's earnings to clock a compound annual growth rate (CAGR) of nearly 25% for the next five years. At its current valuation, buying this tech stock is a no-brainer.","news_type":1},"isVote":1,"tweetType":1,"viewCount":506,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":810055575,"gmtCreate":1629936298197,"gmtModify":1676530175506,"author":{"id":"3585337577037707","authorId":"3585337577037707","name":"JieYee","avatar":"https://static.tigerbbs.com/3e4b8be34071a883cb274790cad527e5","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585337577037707","authorIdStr":"3585337577037707"},"themes":[],"htmlText":"hi","listText":"hi","text":"hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/810055575","repostId":"2162044051","repostType":4,"repost":{"id":"2162044051","pubTimestamp":1629901503,"share":"https://ttm.financial/m/news/2162044051?lang=&edition=fundamental","pubTime":"2021-08-25 22:25","market":"us","language":"en","title":"Here's Why You Should Stay Away From Coinbase Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2162044051","media":"Motley Fool","summary":"The cryptocurrency platform faces a challenging situation ahead, which casts doubt on its investment merits.","content":"<p><b><a href=\"https://laohu8.com/S/COIN\">Coinbase Global, Inc.</a> </b>(NASDAQ:COIN) has become a popular name among investors who want exposure to cryptocurrencies via the stock market. Although its share price has fallen over 25% since going public in April, the business's growth is undeniable. Revenue in the second quarter topped $2 billion, more than 11 times what the company reported in the prior-year period.</p>\n<p>It might sound like I'm pitching Coinbase, but that's not the case. There are serious concerns investors need to think about if they're considering buying this stock, and it all hinges on the volatility of digital assets.</p>\n<p>Here's why Coinbase is in a difficult spot no matter what happens with cryptocurrency.</p>\n<p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F640293%2Fcoinbase-7.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Coinbase.</p>\n<h2>If the volatility stays&nbsp;</h2>\n<p>Everyone knows cryptocurrencies are extremely volatile. <b>Bitcoin</b>, the&nbsp;largest&nbsp;cryptocurrency&nbsp;by&nbsp;market capitalization, has been on a roller-coaster ride this year. Its price soared more than 100% by mid-April, only to give up all of those gains just three months later. <b>Ethereum</b>, No. 2 by market cap, has&nbsp;experienced an even wilder&nbsp;ride&nbsp;in 2021.</p>\n<p>Huge day-to-day price swings are the norm, and for Coinbase, this has been a boon. The company's monthly transacting users grew from 1.5 million in the second quarter last year to 8.8 million in 2021. Additionally, trading volume has skyrocketed to almost half a trillion dollars.</p>\n<p>Coinbase's success is highly dependent on the volatility of the cryptocurrency market. The company derives 95% of its revenue from transaction fees with both retail and institutional clients trading on its platform. While this has so far been lucrative, Coinbase has received criticism over its high fees, and there are many other cryptocurrency exchanges out there eagerly looking to fill users' needs.</p>\n<p>This makes me think of how companies like <b>Charles Schwab</b>&nbsp;and&nbsp;<b>Robinhood</b> now offer zero-dollar stock trades. What happens to Coinbase's business if fees race toward zero as a result of increased competition? The company is thriving today, but the tiny services segment better start growing meaningfully if Coinbase wants to keep itself differentiated enough to achieve long-term success.&nbsp;</p>\n<p>And then there's the fact cryptocurrencies were never meant to be a speculative financial asset. One of the main goals of Bitcoin, for example, is to democratize finance, and increasing utility can only happen if volatility significantly drops, which would present yet another problem for Coinbase.&nbsp;</p>\n<h2>If the volatility goes&nbsp;</h2>\n<p>Major investment banks like&nbsp;<b>Goldman Sachs</b> and&nbsp;<b>JPMorgan Chase</b> experience huge fluctuations in their trading divisions' performances each quarter. Unsurprisingly, when the stock market is hitting all-time highs and volatility is elevated, revenue gets a boost. This is largely unpredictable, and these financial institutions are successful long term, because they offer other value-added services.&nbsp;</p>\n<p>As previously mentioned, Coinbase needs to strengthen its non-transaction business and align itself for a situation where cryptocurrency utility rises. And it can't just focus on clients' investment and speculative needs. In addition to hedging against the potential for wide fluctuations quarter to quarter, Coinbase must prepare for cryptocurrencies to eventually fulfill their purpose of going mainstream. For Bitcoin, this ultimately means being used as a medium of exchange.&nbsp;</p>\n<p>If people start transacting with Bitcoin more in their daily financial lives, then its volatility must have fallen substantially. This is what many cryptocurrency enthusiasts are hoping for, and it would deal a direct blow to Coinbase's bread-and-butter trading business. A huge fintech player&nbsp;like&nbsp;<b><a href=\"https://laohu8.com/S/PYPL\">PayPal</a></b>, with its massive user base consisting of more than 400&nbsp;million consumers and merchants, already lets people make purchases and check out with cryptocurrency. Can Coinbase shift from a facilitator of speculation to <a href=\"https://laohu8.com/S/AONE.U\">one</a> of utility? I don't have the answer.&nbsp;</p>\n<p>Coinbase is clearly growing at the moment, but I remain bearish as the company faces some fundamental hurdles. If cryptocurrency volatility stays high, competing services can chip away at Coinbase's booming transaction revenue by reducing their fees. On the other hand, if cryptocurrencies, and mainly Bitcoin, see their volatility fall, Coinbase's profit machine is left for dead.&nbsp;</p>\n<p>That's why I suggest staying away from the stock.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why You Should Stay Away From Coinbase Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why You Should Stay Away From Coinbase Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-25 22:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/25/heres-why-you-should-stay-away-from-coinbase-stock/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Coinbase Global, Inc. (NASDAQ:COIN) has become a popular name among investors who want exposure to cryptocurrencies via the stock market. Although its share price has fallen over 25% since going ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/25/heres-why-you-should-stay-away-from-coinbase-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"COIN":"Coinbase Global, Inc."},"source_url":"https://www.fool.com/investing/2021/08/25/heres-why-you-should-stay-away-from-coinbase-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2162044051","content_text":"Coinbase Global, Inc. (NASDAQ:COIN) has become a popular name among investors who want exposure to cryptocurrencies via the stock market. Although its share price has fallen over 25% since going public in April, the business's growth is undeniable. Revenue in the second quarter topped $2 billion, more than 11 times what the company reported in the prior-year period.\nIt might sound like I'm pitching Coinbase, but that's not the case. There are serious concerns investors need to think about if they're considering buying this stock, and it all hinges on the volatility of digital assets.\nHere's why Coinbase is in a difficult spot no matter what happens with cryptocurrency.\n\nImage source: Coinbase.\nIf the volatility stays \nEveryone knows cryptocurrencies are extremely volatile. Bitcoin, the largest cryptocurrency by market capitalization, has been on a roller-coaster ride this year. Its price soared more than 100% by mid-April, only to give up all of those gains just three months later. Ethereum, No. 2 by market cap, has experienced an even wilder ride in 2021.\nHuge day-to-day price swings are the norm, and for Coinbase, this has been a boon. The company's monthly transacting users grew from 1.5 million in the second quarter last year to 8.8 million in 2021. Additionally, trading volume has skyrocketed to almost half a trillion dollars.\nCoinbase's success is highly dependent on the volatility of the cryptocurrency market. The company derives 95% of its revenue from transaction fees with both retail and institutional clients trading on its platform. While this has so far been lucrative, Coinbase has received criticism over its high fees, and there are many other cryptocurrency exchanges out there eagerly looking to fill users' needs.\nThis makes me think of how companies like Charles Schwab and Robinhood now offer zero-dollar stock trades. What happens to Coinbase's business if fees race toward zero as a result of increased competition? The company is thriving today, but the tiny services segment better start growing meaningfully if Coinbase wants to keep itself differentiated enough to achieve long-term success. \nAnd then there's the fact cryptocurrencies were never meant to be a speculative financial asset. One of the main goals of Bitcoin, for example, is to democratize finance, and increasing utility can only happen if volatility significantly drops, which would present yet another problem for Coinbase. \nIf the volatility goes \nMajor investment banks like Goldman Sachs and JPMorgan Chase experience huge fluctuations in their trading divisions' performances each quarter. Unsurprisingly, when the stock market is hitting all-time highs and volatility is elevated, revenue gets a boost. This is largely unpredictable, and these financial institutions are successful long term, because they offer other value-added services. \nAs previously mentioned, Coinbase needs to strengthen its non-transaction business and align itself for a situation where cryptocurrency utility rises. And it can't just focus on clients' investment and speculative needs. In addition to hedging against the potential for wide fluctuations quarter to quarter, Coinbase must prepare for cryptocurrencies to eventually fulfill their purpose of going mainstream. For Bitcoin, this ultimately means being used as a medium of exchange. \nIf people start transacting with Bitcoin more in their daily financial lives, then its volatility must have fallen substantially. This is what many cryptocurrency enthusiasts are hoping for, and it would deal a direct blow to Coinbase's bread-and-butter trading business. A huge fintech player like PayPal, with its massive user base consisting of more than 400 million consumers and merchants, already lets people make purchases and check out with cryptocurrency. Can Coinbase shift from a facilitator of speculation to one of utility? I don't have the answer. \nCoinbase is clearly growing at the moment, but I remain bearish as the company faces some fundamental hurdles. If cryptocurrency volatility stays high, competing services can chip away at Coinbase's booming transaction revenue by reducing their fees. On the other hand, if cryptocurrencies, and mainly Bitcoin, see their volatility fall, Coinbase's profit machine is left for dead. \nThat's why I suggest staying away from the stock.","news_type":1},"isVote":1,"tweetType":1,"viewCount":604,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":810056448,"gmtCreate":1629936225384,"gmtModify":1676530175474,"author":{"id":"3585337577037707","authorId":"3585337577037707","name":"JieYee","avatar":"https://static.tigerbbs.com/3e4b8be34071a883cb274790cad527e5","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585337577037707","authorIdStr":"3585337577037707"},"themes":[],"htmlText":"hi","listText":"hi","text":"hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/810056448","repostId":"2162539710","repostType":4,"repost":{"id":"2162539710","pubTimestamp":1629934200,"share":"https://ttm.financial/m/news/2162539710?lang=&edition=fundamental","pubTime":"2021-08-26 07:30","market":"us","language":"en","title":"Johnson & Johnson  Announces Data to Support Boosting its Single-Shot COVID-19 Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2162539710","media":"StreetInsider","summary":"Johnson & Johnson (NYSE: JNJ) (the Company) today announced data supporting the use of its COVID-19 ","content":"<p>Johnson &amp; Johnson (NYSE: JNJ) (the Company) today announced data supporting the use of its COVID-19 vaccine as a booster shot for people previously vaccinated with the single-shot Johnson &amp; Johnson vaccine.</p>\n<p>In July, the Company reported interim Phase 1/2a data published in the <i>New England Journal of Medicine</i> that demonstrated neutralizing antibody responses generated by the Johnson &amp; Johnson single-shot COVID-19 vaccine were strong and stable through eight months after immunization.</p>\n<p>In anticipation of the potential need for boosters, the Company conducted two Phase 1/2a studies in individuals previously vaccinated with its single-shot vaccine. New interim data from these studies demonstrate that a booster dose of the Johnson &amp; Johnson COVID-19 vaccine generated a rapid and robust increase in spike-binding antibodies, nine-fold higher than 28 days after the primary single-dose vaccination. Significant increases in binding antibody responses were observed in participants between ages 18 and 55, and in those 65 years and older who received a lower booster dose. The study summaries were submitted to <i>medRxiv</i> on August 24.</p>\n<p>\"We have established that a single shot of our COVID-19 vaccine generates strong and robust immune responses that are durable and persistent through eight months. With these new data, we also see that a booster dose of the Johnson &amp; Johnson COVID-19 vaccine further increases antibody responses among study participants who had previously received our vaccine,\" said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research &amp; Development, Johnson &amp; Johnson. \"We look forward to discussing with public health officials a potential strategy for our Johnson &amp; Johnson COVID-19 vaccine, boosting eight months or longer after the primary single-dose vaccination.\"</p>\n<p>The Company is engaging with the U.S. Food and Drug Administration (FDA), U.S. Centers for Disease Control and Prevention (CDC), European Medicines Agency (EMA) and other health authorities regarding boosting with the Johnson &amp; Johnson COVID-19 vaccine. Johnson &amp; Johnson continues to diligently generate and evaluate data from ongoing trials as well as emerging real-world evidence.</p>\n<p>The Phase 1/2a clinical trials (VAC31518COV1001 and VAC31518COV2001) have been funded in part with federal funds from the U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (BARDA), under other transaction authority (\"OTA\") agreement No. HHSO100201700018C.</p>\n<p>For more information on the Company's multi-pronged approach to helping combat the pandemic, visit: www.jnj.com/covid-19.</p>\n<p><b>Authorized Use </b>The Janssen COVID-19 vaccine is authorized for use in the U.S. under an Emergency Use Authorization (EUA) for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 18 years of age and older.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Johnson & Johnson  Announces Data to Support Boosting its Single-Shot COVID-19 Vaccine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJohnson & Johnson  Announces Data to Support Boosting its Single-Shot COVID-19 Vaccine\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-26 07:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18860180><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Johnson & Johnson (NYSE: JNJ) (the Company) today announced data supporting the use of its COVID-19 vaccine as a booster shot for people previously vaccinated with the single-shot Johnson & Johnson ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18860180\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18860180","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2162539710","content_text":"Johnson & Johnson (NYSE: JNJ) (the Company) today announced data supporting the use of its COVID-19 vaccine as a booster shot for people previously vaccinated with the single-shot Johnson & Johnson vaccine.\nIn July, the Company reported interim Phase 1/2a data published in the New England Journal of Medicine that demonstrated neutralizing antibody responses generated by the Johnson & Johnson single-shot COVID-19 vaccine were strong and stable through eight months after immunization.\nIn anticipation of the potential need for boosters, the Company conducted two Phase 1/2a studies in individuals previously vaccinated with its single-shot vaccine. New interim data from these studies demonstrate that a booster dose of the Johnson & Johnson COVID-19 vaccine generated a rapid and robust increase in spike-binding antibodies, nine-fold higher than 28 days after the primary single-dose vaccination. Significant increases in binding antibody responses were observed in participants between ages 18 and 55, and in those 65 years and older who received a lower booster dose. The study summaries were submitted to medRxiv on August 24.\n\"We have established that a single shot of our COVID-19 vaccine generates strong and robust immune responses that are durable and persistent through eight months. With these new data, we also see that a booster dose of the Johnson & Johnson COVID-19 vaccine further increases antibody responses among study participants who had previously received our vaccine,\" said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, Johnson & Johnson. \"We look forward to discussing with public health officials a potential strategy for our Johnson & Johnson COVID-19 vaccine, boosting eight months or longer after the primary single-dose vaccination.\"\nThe Company is engaging with the U.S. Food and Drug Administration (FDA), U.S. Centers for Disease Control and Prevention (CDC), European Medicines Agency (EMA) and other health authorities regarding boosting with the Johnson & Johnson COVID-19 vaccine. Johnson & Johnson continues to diligently generate and evaluate data from ongoing trials as well as emerging real-world evidence.\nThe Phase 1/2a clinical trials (VAC31518COV1001 and VAC31518COV2001) have been funded in part with federal funds from the U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (BARDA), under other transaction authority (\"OTA\") agreement No. HHSO100201700018C.\nFor more information on the Company's multi-pronged approach to helping combat the pandemic, visit: www.jnj.com/covid-19.\nAuthorized Use The Janssen COVID-19 vaccine is authorized for use in the U.S. under an Emergency Use Authorization (EUA) for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 18 years of age and older.","news_type":1},"isVote":1,"tweetType":1,"viewCount":610,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":810056063,"gmtCreate":1629936203352,"gmtModify":1676530175447,"author":{"id":"3585337577037707","authorId":"3585337577037707","name":"JieYee","avatar":"https://static.tigerbbs.com/3e4b8be34071a883cb274790cad527e5","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585337577037707","authorIdStr":"3585337577037707"},"themes":[],"htmlText":"[Strong]&nbsp;","listText":"[Strong]&nbsp;","text":"[Strong]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/810056063","repostId":"2162005536","repostType":4,"isVote":1,"tweetType":1,"viewCount":540,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":835528530,"gmtCreate":1629727920620,"gmtModify":1676530113980,"author":{"id":"3585337577037707","authorId":"3585337577037707","name":"JieYee","avatar":"https://static.tigerbbs.com/3e4b8be34071a883cb274790cad527e5","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585337577037707","authorIdStr":"3585337577037707"},"themes":[],"htmlText":"hi","listText":"hi","text":"hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/835528530","repostId":"1123162430","repostType":4,"isVote":1,"tweetType":1,"viewCount":460,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":813654346,"gmtCreate":1630200746485,"gmtModify":1676530241235,"author":{"id":"3585337577037707","authorId":"3585337577037707","name":"JieYee","avatar":"https://static.tigerbbs.com/3e4b8be34071a883cb274790cad527e5","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585337577037707","authorIdStr":"3585337577037707"},"themes":[],"htmlText":"hi","listText":"hi","text":"hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/813654346","repostId":"2162024053","repostType":4,"repost":{"id":"2162024053","pubTimestamp":1630110600,"share":"https://ttm.financial/m/news/2162024053?lang=&edition=fundamental","pubTime":"2021-08-28 08:30","market":"us","language":"en","title":"Got $1,000? Buy This Hot Stock That Jumped 10X and Could Do It Again","url":"https://stock-news.laohu8.com/highlight/detail?id=2162024053","media":"Motley Fool","summary":"A stronger pace of growth in the future, thanks to solid demand, could send this tech stock's price much higher.","content":"<p><b>Applied Materials</b> (NASDAQ:AMAT) looked like an enticing bet going into its fiscal 2021 third-quarter earnings report, and the company didn't disappoint as it crushed Wall Street's expectations on the back of terrific growth in revenue and earnings. What's more, Applied's guidance turned out to be strong as well, fueled by the massive growth in semiconductor investments across the globe as chipmakers are scrambling to meet huge end-market demand.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/36e7c524b510f3ddf875d48fa2f3ac29\" tg-width=\"700\" tg-height=\"393\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<p>It's worth noting that Applied Materials stock is now trading at a cheaper valuation than it was before the quarterly report came out, thanks to the terrific earnings growth. Its price-to-earnings (P/E) ratio is just 23, while the forward earnings multiple of 17 indicates that more bottom-line growth is in the cards. These multiples are lower than the <b>S&amp;P 500 Index</b>'s trailing P/E of 31 and forward P/E of 22.</p>\n<p>That means there's a golden opportunity for investors to add a rapidly growing company to their portfolios at an attractive valuation, and they shouldn't miss out. Let's look at some reasons.</p>\n<h2>Applied Materials is now growing at a blistering pace</h2>\n<p>A $1,000 investment in Applied Materials stock a decade ago would be worth almost $12,000 now:</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/81e0104d17e81fcbfbe06af299b88f05\" tg-width=\"720\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>AMAT data by YCharts.</span></p>\n<p>However, as the chart above shows, the company's top and bottom lines haven't exactly grown at a blistering pace over the past 10 years. Its revenue just about doubled, while earnings growth hasn't been eye-popping either, considering the pace at which the broader market's bottom line has increased. Also, as the chart indicates, most of Applied Materials' gains arrived in the past year and a half, after it became evident that the company's offerings would remain in hot demand amid a global semiconductor shortage that has disrupted several industries.</p>\n<p>Not surprisingly, Applied Materials' revenue and earnings have been growing at a much faster pace when compared to its average annual growth in the past 10 years. The company delivered record quarterly revenue of $6.2 billion in Q3, up 41% year over year. It also clocked a record (adjusted) operating margin of 32.7%, a jump of 6.3 percentage points over the prior year.</p>\n<p>The terrific sales and margin growth led to record adjusted earnings of $1.90 per share, up 79% from the year-ago quarter. The results crushed the expectations of analysts who'd been looking for $1.77 per share in earnings on $5.94 billion in revenue.</p>\n<p>Applied Materials' guidance was the icing on the cake. The company expects, at the midpoint of its guidance range, to earn $1.94 per share this quarter on revenue of $6.33 billion. Wall Street had set the bar lower; analysts were expecting just $1.81 in earnings per share on $6.04 billion in revenue. The midpoint of the guidance indicates that Applied is anticipating 35% year-over-year revenue growth this quarter, while non-GAAP (adjusted) earnings could increase 55%.</p>\n<p>The impressive guidance is a clue that Applied Materials has switched into a higher gear, and it's unlikely to step off the gas given the massive end-market opportunity at hand. In fact, it wouldn't be surprising to see its growth over the next decade significantly outpacing the rate at which it's grown in the past 10 years, helping the stock to fly higher once again.</p>\n<h2>Sustainable growth drivers can help the stock soar</h2>\n<p>Applied Materials supplies chip fabrication equipment, services, and software to semiconductor manufacturers. Its largest source of revenue is the semiconductor systems business, through which Applied develops, manufactures, and sells semiconductor fabrication equipment. This segment produced nearly 72% of the company's total revenue last quarter and recorded 53% year-over-year growth.</p>\n<p>Within the semiconductor systems business, the foundry/logic vertical occupied the largest share with 63% of total revenue, up from 55% in the year-ago quarter. The foundry business is built for long-term growth, as chipmakers across the globe are ramping up capacity. For instance, global semiconductor capital spending stood at an estimated $29.4 billion in 2010, according to <b>Gartner</b>. Last year, that number had ballooned to $106.9 billion.</p>\n<p>Gartner estimates that global semiconductor spending will rise to $141.9 billion this year. Spending on semiconductor equipment can keep moving higher in the coming years on the back of a huge jump in chip demand.</p>\n<p>Applied Materials points out that the semiconductor industry took 40 years to achieve its first $200 billion in revenue; from 2000 to 2017, the industry added the next $200 billion. An additional $200 billion of revenue is expected by 2024, over a shorter span of just seven years. What's more, the semiconductor industry's revenue is anticipated to increase a whopping $400 billion from 2025 to 2030, hitting $1 trillion at the end of the forecast period.</p>\n<p>Chipmakers will need to buy new equipment or upgrade their existing setups to cater to this massive increase in semiconductor demand, which will be driven by several verticals including automotive, networking, and industrial. Discussing \"PPACt\" (chip power efficiency, performance, area, cost, and time to market), Applied Materials CEO Gary Dickerson said on the Q3 earnings call that the company is on track to take advantage of these tailwinds and outperform the broader market:</p>\n<blockquote>\n As we look ahead, we are confident that the strength of longer-term secular trends will drive semiconductor and wafer fab equipment markets structurally higher. And we believe Applied is in the best position to accelerate our customers' PPACt roadmaps, and grow significantly faster than our markets.\n</blockquote>\n<p>All of this indicates that Applied Materials is in a solid position to deliver more upside. Analysts expect the company's earnings to clock a compound annual growth rate (CAGR) of nearly 25% for the next five years. At its current valuation, buying this tech stock is a no-brainer.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Got $1,000? Buy This Hot Stock That Jumped 10X and Could Do It Again</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGot $1,000? Buy This Hot Stock That Jumped 10X and Could Do It Again\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-28 08:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/27/got-1000-buy-this-hot-stock-that-could-jump-10x-on/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Applied Materials (NASDAQ:AMAT) looked like an enticing bet going into its fiscal 2021 third-quarter earnings report, and the company didn't disappoint as it crushed Wall Street's expectations on the ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/27/got-1000-buy-this-hot-stock-that-could-jump-10x-on/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMAT":"应用材料"},"source_url":"https://www.fool.com/investing/2021/08/27/got-1000-buy-this-hot-stock-that-could-jump-10x-on/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2162024053","content_text":"Applied Materials (NASDAQ:AMAT) looked like an enticing bet going into its fiscal 2021 third-quarter earnings report, and the company didn't disappoint as it crushed Wall Street's expectations on the back of terrific growth in revenue and earnings. What's more, Applied's guidance turned out to be strong as well, fueled by the massive growth in semiconductor investments across the globe as chipmakers are scrambling to meet huge end-market demand.\nImage source: Getty Images.\nIt's worth noting that Applied Materials stock is now trading at a cheaper valuation than it was before the quarterly report came out, thanks to the terrific earnings growth. Its price-to-earnings (P/E) ratio is just 23, while the forward earnings multiple of 17 indicates that more bottom-line growth is in the cards. These multiples are lower than the S&P 500 Index's trailing P/E of 31 and forward P/E of 22.\nThat means there's a golden opportunity for investors to add a rapidly growing company to their portfolios at an attractive valuation, and they shouldn't miss out. Let's look at some reasons.\nApplied Materials is now growing at a blistering pace\nA $1,000 investment in Applied Materials stock a decade ago would be worth almost $12,000 now:\nAMAT data by YCharts.\nHowever, as the chart above shows, the company's top and bottom lines haven't exactly grown at a blistering pace over the past 10 years. Its revenue just about doubled, while earnings growth hasn't been eye-popping either, considering the pace at which the broader market's bottom line has increased. Also, as the chart indicates, most of Applied Materials' gains arrived in the past year and a half, after it became evident that the company's offerings would remain in hot demand amid a global semiconductor shortage that has disrupted several industries.\nNot surprisingly, Applied Materials' revenue and earnings have been growing at a much faster pace when compared to its average annual growth in the past 10 years. The company delivered record quarterly revenue of $6.2 billion in Q3, up 41% year over year. It also clocked a record (adjusted) operating margin of 32.7%, a jump of 6.3 percentage points over the prior year.\nThe terrific sales and margin growth led to record adjusted earnings of $1.90 per share, up 79% from the year-ago quarter. The results crushed the expectations of analysts who'd been looking for $1.77 per share in earnings on $5.94 billion in revenue.\nApplied Materials' guidance was the icing on the cake. The company expects, at the midpoint of its guidance range, to earn $1.94 per share this quarter on revenue of $6.33 billion. Wall Street had set the bar lower; analysts were expecting just $1.81 in earnings per share on $6.04 billion in revenue. The midpoint of the guidance indicates that Applied is anticipating 35% year-over-year revenue growth this quarter, while non-GAAP (adjusted) earnings could increase 55%.\nThe impressive guidance is a clue that Applied Materials has switched into a higher gear, and it's unlikely to step off the gas given the massive end-market opportunity at hand. In fact, it wouldn't be surprising to see its growth over the next decade significantly outpacing the rate at which it's grown in the past 10 years, helping the stock to fly higher once again.\nSustainable growth drivers can help the stock soar\nApplied Materials supplies chip fabrication equipment, services, and software to semiconductor manufacturers. Its largest source of revenue is the semiconductor systems business, through which Applied develops, manufactures, and sells semiconductor fabrication equipment. This segment produced nearly 72% of the company's total revenue last quarter and recorded 53% year-over-year growth.\nWithin the semiconductor systems business, the foundry/logic vertical occupied the largest share with 63% of total revenue, up from 55% in the year-ago quarter. The foundry business is built for long-term growth, as chipmakers across the globe are ramping up capacity. For instance, global semiconductor capital spending stood at an estimated $29.4 billion in 2010, according to Gartner. Last year, that number had ballooned to $106.9 billion.\nGartner estimates that global semiconductor spending will rise to $141.9 billion this year. Spending on semiconductor equipment can keep moving higher in the coming years on the back of a huge jump in chip demand.\nApplied Materials points out that the semiconductor industry took 40 years to achieve its first $200 billion in revenue; from 2000 to 2017, the industry added the next $200 billion. An additional $200 billion of revenue is expected by 2024, over a shorter span of just seven years. What's more, the semiconductor industry's revenue is anticipated to increase a whopping $400 billion from 2025 to 2030, hitting $1 trillion at the end of the forecast period.\nChipmakers will need to buy new equipment or upgrade their existing setups to cater to this massive increase in semiconductor demand, which will be driven by several verticals including automotive, networking, and industrial. Discussing \"PPACt\" (chip power efficiency, performance, area, cost, and time to market), Applied Materials CEO Gary Dickerson said on the Q3 earnings call that the company is on track to take advantage of these tailwinds and outperform the broader market:\n\n As we look ahead, we are confident that the strength of longer-term secular trends will drive semiconductor and wafer fab equipment markets structurally higher. And we believe Applied is in the best position to accelerate our customers' PPACt roadmaps, and grow significantly faster than our markets.\n\nAll of this indicates that Applied Materials is in a solid position to deliver more upside. Analysts expect the company's earnings to clock a compound annual growth rate (CAGR) of nearly 25% for the next five years. At its current valuation, buying this tech stock is a no-brainer.","news_type":1},"isVote":1,"tweetType":1,"viewCount":506,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":813657386,"gmtCreate":1630200820645,"gmtModify":1676530241250,"author":{"id":"3585337577037707","authorId":"3585337577037707","name":"JieYee","avatar":"https://static.tigerbbs.com/3e4b8be34071a883cb274790cad527e5","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585337577037707","authorIdStr":"3585337577037707"},"themes":[],"htmlText":"very great and useful article for all buyers&nbsp;","listText":"very great and useful article for all buyers&nbsp;","text":"very great and useful article for all buyers","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/813657386","repostId":"2162707824","repostType":4,"repost":{"id":"2162707824","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1630104635,"share":"https://ttm.financial/m/news/2162707824?lang=&edition=fundamental","pubTime":"2021-08-28 06:50","market":"us","language":"en","title":"U.S. resumes supply of Lilly's COVID-19 antibody combo to some states","url":"https://stock-news.laohu8.com/highlight/detail?id=2162707824","media":"Reuters","summary":"Aug 27 (Reuters) - U.S. health officials on Friday decided to resume the supply of Eli Lilly's COVID","content":"<p>Aug 27 (Reuters) - U.S. health officials on Friday decided to resume the supply of Eli Lilly's COVID-19 antibody cocktail to states where variants resistant to it are low, saying the therapy could work against the fast-spreading Delta variant based on lab studies.</p>\n<p>The Department of Health and Human Services narrowed the scope of authorization for the dual-antibody therapy, bamlanivimab and etesevimab, to states including Colorado, Connecticut and Illinois, Indiana.</p>\n<p>With the Delta variant becoming the dominant strain, the prevalence of variants resistant to the therapy is steadily decreasing, the agency said</p>\n<p>Based on lab tests, the drugs administered together are expected to retain activity against the Delta variant, but not against Delta plus and variants first identified in Brazil, South Africa and Colombia, it said.</p>\n<p>The department had in June paused its distribution after the therapy failed to show effectiveness against the coronavirus variants that were first identified in Brazil and South Africa.</p>\n<p>The supply of standalone etesevimab to be paired with existing supply of bamlanivimab is also being resumed to some states.</p>\n<p>Regeneron's antibody therapy REGEN-COV, and GlaxoSmithKline Plc and partner Vir Biotechnology's</p>\n<p>sotrovimab may be used in all states, territories, and U.S. jurisdictions as they are likely to be effective against most variants including Delta, the agency said.</p>\n<p>Bamlanivimab and etesevimab, REGEN-COV and sotrovimab are authorized for use in people 12 years and above with mild-to-moderate infection and are at high risk for progression to severe COVID-19.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. resumes supply of Lilly's COVID-19 antibody combo to some states</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. resumes supply of Lilly's COVID-19 antibody combo to some states\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-08-28 06:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Aug 27 (Reuters) - U.S. health officials on Friday decided to resume the supply of Eli Lilly's COVID-19 antibody cocktail to states where variants resistant to it are low, saying the therapy could work against the fast-spreading Delta variant based on lab studies.</p>\n<p>The Department of Health and Human Services narrowed the scope of authorization for the dual-antibody therapy, bamlanivimab and etesevimab, to states including Colorado, Connecticut and Illinois, Indiana.</p>\n<p>With the Delta variant becoming the dominant strain, the prevalence of variants resistant to the therapy is steadily decreasing, the agency said</p>\n<p>Based on lab tests, the drugs administered together are expected to retain activity against the Delta variant, but not against Delta plus and variants first identified in Brazil, South Africa and Colombia, it said.</p>\n<p>The department had in June paused its distribution after the therapy failed to show effectiveness against the coronavirus variants that were first identified in Brazil and South Africa.</p>\n<p>The supply of standalone etesevimab to be paired with existing supply of bamlanivimab is also being resumed to some states.</p>\n<p>Regeneron's antibody therapy REGEN-COV, and GlaxoSmithKline Plc and partner Vir Biotechnology's</p>\n<p>sotrovimab may be used in all states, territories, and U.S. jurisdictions as they are likely to be effective against most variants including Delta, the agency said.</p>\n<p>Bamlanivimab and etesevimab, REGEN-COV and sotrovimab are authorized for use in people 12 years and above with mild-to-moderate infection and are at high risk for progression to severe COVID-19.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VIR":"Vir Biotechnology, Inc.","LLY":"礼来","REGN":"再生元制药公司"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2162707824","content_text":"Aug 27 (Reuters) - U.S. health officials on Friday decided to resume the supply of Eli Lilly's COVID-19 antibody cocktail to states where variants resistant to it are low, saying the therapy could work against the fast-spreading Delta variant based on lab studies.\nThe Department of Health and Human Services narrowed the scope of authorization for the dual-antibody therapy, bamlanivimab and etesevimab, to states including Colorado, Connecticut and Illinois, Indiana.\nWith the Delta variant becoming the dominant strain, the prevalence of variants resistant to the therapy is steadily decreasing, the agency said\nBased on lab tests, the drugs administered together are expected to retain activity against the Delta variant, but not against Delta plus and variants first identified in Brazil, South Africa and Colombia, it said.\nThe department had in June paused its distribution after the therapy failed to show effectiveness against the coronavirus variants that were first identified in Brazil and South Africa.\nThe supply of standalone etesevimab to be paired with existing supply of bamlanivimab is also being resumed to some states.\nRegeneron's antibody therapy REGEN-COV, and GlaxoSmithKline Plc and partner Vir Biotechnology's\nsotrovimab may be used in all states, territories, and U.S. jurisdictions as they are likely to be effective against most variants including Delta, the agency said.\nBamlanivimab and etesevimab, REGEN-COV and sotrovimab are authorized for use in people 12 years and above with mild-to-moderate infection and are at high risk for progression to severe COVID-19.","news_type":1},"isVote":1,"tweetType":1,"viewCount":501,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":810056063,"gmtCreate":1629936203352,"gmtModify":1676530175447,"author":{"id":"3585337577037707","authorId":"3585337577037707","name":"JieYee","avatar":"https://static.tigerbbs.com/3e4b8be34071a883cb274790cad527e5","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585337577037707","authorIdStr":"3585337577037707"},"themes":[],"htmlText":"[Strong]&nbsp;","listText":"[Strong]&nbsp;","text":"[Strong]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/810056063","repostId":"2162005536","repostType":4,"repost":{"id":"2162005536","pubTimestamp":1629934980,"share":"https://ttm.financial/m/news/2162005536?lang=&edition=fundamental","pubTime":"2021-08-26 07:43","market":"us","language":"en","title":"Dick's Sporting Goods Tops Q2 EPS by $2.38, Raises Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2162005536","media":"StreetInsider","summary":"Dick's Sporting Goods (NYSE: DKS) reported Q2 EPS of $5.08, $2.38 better than the analyst estimate o","content":"<p>Dick's Sporting Goods (NYSE: DKS) reported Q2 EPS of $5.08, $2.38 better than the analyst estimate of $2.70. Revenue for the quarter came in at $3.27 billion versus the consensus estimate of $2.82 billion.</p>\n<p>\"We said 2021 was going to be the most transformational year in our history, and so far, it certainly has been. We continue to perform at a very high level and invest in our future to reimagine the athlete experience in our core business and with new concepts,\" said Ed Stack, Executive Chairman. \"I am very pleased with the strength of our business and confident about our growth opportunities.\"</p>\n<p>\"Our record-breaking quarterly sales and earnings significantly exceeded our expectations, reflecting continued strong consumer demand across our diverse category portfolio along with the strength of our omni-channel offering and elevated athlete experience. I'd like to thank all our teammates for how they delivered against our core strategies and for their commitment to DICK'S Sporting Goods, which helped make this performance possible,\" said Lauren Hobart, President and Chief Executive Officer. \"Based on the strength of our business and our expectations for continued strong consumer demand, we are pleased to increase our full year sales and earnings outlook for the second time this year.\"</p>\n<p><b>GUIDANCE:</b></p>\n<p>Dick's Sporting Goods sees FY2021 EPS of $12.45-$12.95, versus the consensus of $9.01. Dick's Sporting Goods sees FY2021 revenue of $11.52-11.72 billion, versus the consensus of $10.9 billion.</p>\n<p><b>RAISED AND SPECIAL DIVIDEND:</b></p>\n<p>The Company announces enhancements to its 2021 capital allocation plan, including a special dividend of $5.50 per share, a 21% increase in its quarterly dividend to $0.4375 per share and an increase in its planned share repurchases to a minimum of $400 million.</p>\n<p>\"This additional cash return to our shareholders demonstrates the confidence we have in our business, the strength of our balance sheet and a commitment to efficiently deploy our cash,\" said Lauren Hobart, President and Chief Executive Officer. \"We continue to remain firmly committed to investing in the profitable growth of our core business.\"</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dick's Sporting Goods Tops Q2 EPS by $2.38, Raises Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDick's Sporting Goods Tops Q2 EPS by $2.38, Raises Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-26 07:43 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18860450><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Dick's Sporting Goods (NYSE: DKS) reported Q2 EPS of $5.08, $2.38 better than the analyst estimate of $2.70. Revenue for the quarter came in at $3.27 billion versus the consensus estimate of $2.82 ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18860450\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"QTWO":"Q2 Holdings Inc","DKS":"迪克体育用品"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18860450","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2162005536","content_text":"Dick's Sporting Goods (NYSE: DKS) reported Q2 EPS of $5.08, $2.38 better than the analyst estimate of $2.70. Revenue for the quarter came in at $3.27 billion versus the consensus estimate of $2.82 billion.\n\"We said 2021 was going to be the most transformational year in our history, and so far, it certainly has been. We continue to perform at a very high level and invest in our future to reimagine the athlete experience in our core business and with new concepts,\" said Ed Stack, Executive Chairman. \"I am very pleased with the strength of our business and confident about our growth opportunities.\"\n\"Our record-breaking quarterly sales and earnings significantly exceeded our expectations, reflecting continued strong consumer demand across our diverse category portfolio along with the strength of our omni-channel offering and elevated athlete experience. I'd like to thank all our teammates for how they delivered against our core strategies and for their commitment to DICK'S Sporting Goods, which helped make this performance possible,\" said Lauren Hobart, President and Chief Executive Officer. \"Based on the strength of our business and our expectations for continued strong consumer demand, we are pleased to increase our full year sales and earnings outlook for the second time this year.\"\nGUIDANCE:\nDick's Sporting Goods sees FY2021 EPS of $12.45-$12.95, versus the consensus of $9.01. Dick's Sporting Goods sees FY2021 revenue of $11.52-11.72 billion, versus the consensus of $10.9 billion.\nRAISED AND SPECIAL DIVIDEND:\nThe Company announces enhancements to its 2021 capital allocation plan, including a special dividend of $5.50 per share, a 21% increase in its quarterly dividend to $0.4375 per share and an increase in its planned share repurchases to a minimum of $400 million.\n\"This additional cash return to our shareholders demonstrates the confidence we have in our business, the strength of our balance sheet and a commitment to efficiently deploy our cash,\" said Lauren Hobart, President and Chief Executive Officer. \"We continue to remain firmly committed to investing in the profitable growth of our core business.\"","news_type":1},"isVote":1,"tweetType":1,"viewCount":540,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":813640359,"gmtCreate":1630200876071,"gmtModify":1676530241267,"author":{"id":"3585337577037707","authorId":"3585337577037707","name":"JieYee","avatar":"https://static.tigerbbs.com/3e4b8be34071a883cb274790cad527e5","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585337577037707","authorIdStr":"3585337577037707"},"themes":[],"htmlText":"Very interesting, great and useful article to all thereaders. Good job&nbsp;","listText":"Very interesting, great and useful article to all thereaders. Good job&nbsp;","text":"Very interesting, great and useful article to all thereaders. Good job","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/813640359","repostId":"1199074003","repostType":4,"repost":{"id":"1199074003","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1630077382,"share":"https://ttm.financial/m/news/1199074003?lang=&edition=fundamental","pubTime":"2021-08-27 23:16","market":"us","language":"en","title":"Crypto stocks surged in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1199074003","media":"Tiger Newspress","summary":"Crypto stocks surged in morning trading.Bit Digital,Marathon Digital,Riot Blockchain,SoS Ltd,Square,","content":"<p>Crypto stocks surged in morning trading.Bit Digital,Marathon Digital,Riot Blockchain,SoS Ltd,Square,Coinbase&nbsp;and&nbsp;Paypal&nbsp;climbed between 1% and 13%.</p>\n<p><img src=\"https://static.tigerbbs.com/67735af69f95f6a88ee67ae3737e58c0\" tg-width=\"364\" tg-height=\"715\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Crypto stocks surged in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCrypto stocks surged in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-27 23:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Crypto stocks surged in morning trading.Bit Digital,Marathon Digital,Riot Blockchain,SoS Ltd,Square,Coinbase&nbsp;and&nbsp;Paypal&nbsp;climbed between 1% and 13%.</p>\n<p><img src=\"https://static.tigerbbs.com/67735af69f95f6a88ee67ae3737e58c0\" tg-width=\"364\" tg-height=\"715\" width=\"100%\" height=\"auto\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MARA":"Marathon Digital Holdings Inc","SOS":"SOS Limited","EBON":"亿邦国际","NCTY":"第九城市","SQ":"Block","RIOT":"Riot Platforms","BTCM":"BIT Mining","COIN":"Coinbase Global, Inc.","BTBT":"Bit Digital, Inc.","CAN":"嘉楠科技"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199074003","content_text":"Crypto stocks surged in morning trading.Bit Digital,Marathon Digital,Riot Blockchain,SoS Ltd,Square,Coinbase and Paypal climbed between 1% and 13%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":529,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":810055575,"gmtCreate":1629936298197,"gmtModify":1676530175506,"author":{"id":"3585337577037707","authorId":"3585337577037707","name":"JieYee","avatar":"https://static.tigerbbs.com/3e4b8be34071a883cb274790cad527e5","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585337577037707","authorIdStr":"3585337577037707"},"themes":[],"htmlText":"hi","listText":"hi","text":"hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/810055575","repostId":"2162044051","repostType":4,"isVote":1,"tweetType":1,"viewCount":604,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":810056448,"gmtCreate":1629936225384,"gmtModify":1676530175474,"author":{"id":"3585337577037707","authorId":"3585337577037707","name":"JieYee","avatar":"https://static.tigerbbs.com/3e4b8be34071a883cb274790cad527e5","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585337577037707","authorIdStr":"3585337577037707"},"themes":[],"htmlText":"hi","listText":"hi","text":"hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/810056448","repostId":"2162539710","repostType":4,"repost":{"id":"2162539710","pubTimestamp":1629934200,"share":"https://ttm.financial/m/news/2162539710?lang=&edition=fundamental","pubTime":"2021-08-26 07:30","market":"us","language":"en","title":"Johnson & Johnson  Announces Data to Support Boosting its Single-Shot COVID-19 Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2162539710","media":"StreetInsider","summary":"Johnson & Johnson (NYSE: JNJ) (the Company) today announced data supporting the use of its COVID-19 ","content":"<p>Johnson &amp; Johnson (NYSE: JNJ) (the Company) today announced data supporting the use of its COVID-19 vaccine as a booster shot for people previously vaccinated with the single-shot Johnson &amp; Johnson vaccine.</p>\n<p>In July, the Company reported interim Phase 1/2a data published in the <i>New England Journal of Medicine</i> that demonstrated neutralizing antibody responses generated by the Johnson &amp; Johnson single-shot COVID-19 vaccine were strong and stable through eight months after immunization.</p>\n<p>In anticipation of the potential need for boosters, the Company conducted two Phase 1/2a studies in individuals previously vaccinated with its single-shot vaccine. New interim data from these studies demonstrate that a booster dose of the Johnson &amp; Johnson COVID-19 vaccine generated a rapid and robust increase in spike-binding antibodies, nine-fold higher than 28 days after the primary single-dose vaccination. Significant increases in binding antibody responses were observed in participants between ages 18 and 55, and in those 65 years and older who received a lower booster dose. The study summaries were submitted to <i>medRxiv</i> on August 24.</p>\n<p>\"We have established that a single shot of our COVID-19 vaccine generates strong and robust immune responses that are durable and persistent through eight months. With these new data, we also see that a booster dose of the Johnson &amp; Johnson COVID-19 vaccine further increases antibody responses among study participants who had previously received our vaccine,\" said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research &amp; Development, Johnson &amp; Johnson. \"We look forward to discussing with public health officials a potential strategy for our Johnson &amp; Johnson COVID-19 vaccine, boosting eight months or longer after the primary single-dose vaccination.\"</p>\n<p>The Company is engaging with the U.S. Food and Drug Administration (FDA), U.S. Centers for Disease Control and Prevention (CDC), European Medicines Agency (EMA) and other health authorities regarding boosting with the Johnson &amp; Johnson COVID-19 vaccine. Johnson &amp; Johnson continues to diligently generate and evaluate data from ongoing trials as well as emerging real-world evidence.</p>\n<p>The Phase 1/2a clinical trials (VAC31518COV1001 and VAC31518COV2001) have been funded in part with federal funds from the U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (BARDA), under other transaction authority (\"OTA\") agreement No. HHSO100201700018C.</p>\n<p>For more information on the Company's multi-pronged approach to helping combat the pandemic, visit: www.jnj.com/covid-19.</p>\n<p><b>Authorized Use </b>The Janssen COVID-19 vaccine is authorized for use in the U.S. under an Emergency Use Authorization (EUA) for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 18 years of age and older.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Johnson & Johnson  Announces Data to Support Boosting its Single-Shot COVID-19 Vaccine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJohnson & Johnson  Announces Data to Support Boosting its Single-Shot COVID-19 Vaccine\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-26 07:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18860180><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Johnson & Johnson (NYSE: JNJ) (the Company) today announced data supporting the use of its COVID-19 vaccine as a booster shot for people previously vaccinated with the single-shot Johnson & Johnson ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18860180\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18860180","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2162539710","content_text":"Johnson & Johnson (NYSE: JNJ) (the Company) today announced data supporting the use of its COVID-19 vaccine as a booster shot for people previously vaccinated with the single-shot Johnson & Johnson vaccine.\nIn July, the Company reported interim Phase 1/2a data published in the New England Journal of Medicine that demonstrated neutralizing antibody responses generated by the Johnson & Johnson single-shot COVID-19 vaccine were strong and stable through eight months after immunization.\nIn anticipation of the potential need for boosters, the Company conducted two Phase 1/2a studies in individuals previously vaccinated with its single-shot vaccine. New interim data from these studies demonstrate that a booster dose of the Johnson & Johnson COVID-19 vaccine generated a rapid and robust increase in spike-binding antibodies, nine-fold higher than 28 days after the primary single-dose vaccination. Significant increases in binding antibody responses were observed in participants between ages 18 and 55, and in those 65 years and older who received a lower booster dose. The study summaries were submitted to medRxiv on August 24.\n\"We have established that a single shot of our COVID-19 vaccine generates strong and robust immune responses that are durable and persistent through eight months. With these new data, we also see that a booster dose of the Johnson & Johnson COVID-19 vaccine further increases antibody responses among study participants who had previously received our vaccine,\" said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, Johnson & Johnson. \"We look forward to discussing with public health officials a potential strategy for our Johnson & Johnson COVID-19 vaccine, boosting eight months or longer after the primary single-dose vaccination.\"\nThe Company is engaging with the U.S. Food and Drug Administration (FDA), U.S. Centers for Disease Control and Prevention (CDC), European Medicines Agency (EMA) and other health authorities regarding boosting with the Johnson & Johnson COVID-19 vaccine. Johnson & Johnson continues to diligently generate and evaluate data from ongoing trials as well as emerging real-world evidence.\nThe Phase 1/2a clinical trials (VAC31518COV1001 and VAC31518COV2001) have been funded in part with federal funds from the U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (BARDA), under other transaction authority (\"OTA\") agreement No. HHSO100201700018C.\nFor more information on the Company's multi-pronged approach to helping combat the pandemic, visit: www.jnj.com/covid-19.\nAuthorized Use The Janssen COVID-19 vaccine is authorized for use in the U.S. under an Emergency Use Authorization (EUA) for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 18 years of age and older.","news_type":1},"isVote":1,"tweetType":1,"viewCount":610,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":835528530,"gmtCreate":1629727920620,"gmtModify":1676530113980,"author":{"id":"3585337577037707","authorId":"3585337577037707","name":"JieYee","avatar":"https://static.tigerbbs.com/3e4b8be34071a883cb274790cad527e5","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585337577037707","authorIdStr":"3585337577037707"},"themes":[],"htmlText":"hi","listText":"hi","text":"hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/835528530","repostId":"1123162430","repostType":4,"repost":{"id":"1123162430","pubTimestamp":1629725272,"share":"https://ttm.financial/m/news/1123162430?lang=&edition=fundamental","pubTime":"2021-08-23 21:27","market":"us","language":"en","title":"Lyft and Uber shares down after court says California gig worker push is unconstitutional","url":"https://stock-news.laohu8.com/highlight/detail?id=1123162430","media":"CNBC","summary":"KEY POINTS\n\nShares of Uber and Lyft traded lower in the premarket Monday after a California court ru","content":"<div>\n<p>KEY POINTS\n\nShares of Uber and Lyft traded lower in the premarket Monday after a California court ruled that Prop 22, a ballot measure that exempted gig workers from state labor law, was ...</p>\n\n<a href=\"https://www.cnbc.com/2021/08/23/lyft-uber-stocks-fall-after-court-says-gig-worker-push-unconstitutional.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lyft and Uber shares down after court says California gig worker push is unconstitutional</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLyft and Uber shares down after court says California gig worker push is unconstitutional\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-23 21:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/08/23/lyft-uber-stocks-fall-after-court-says-gig-worker-push-unconstitutional.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>KEY POINTS\n\nShares of Uber and Lyft traded lower in the premarket Monday after a California court ruled that Prop 22, a ballot measure that exempted gig workers from state labor law, was ...</p>\n\n<a href=\"https://www.cnbc.com/2021/08/23/lyft-uber-stocks-fall-after-court-says-gig-worker-push-unconstitutional.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"UBER":"优步","LYFT":"Lyft, Inc."},"source_url":"https://www.cnbc.com/2021/08/23/lyft-uber-stocks-fall-after-court-says-gig-worker-push-unconstitutional.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1123162430","content_text":"KEY POINTS\n\nShares of Uber and Lyft traded lower in the premarket Monday after a California court ruled that Prop 22, a ballot measure that exempted gig workers from state labor law, was unconstitutional.\nAlameda County Superior Court Judge Frank Roesch wrote in a ruling late Friday that Proposition 22 is unconstitutional as “it limits the power of a future Legislature to define app-based drivers as workers subject to workers’ compensation law.”\nThe move is a hard hit to gig economy companies that have lobbied for these measures to pass in order for their business models to keep operating as normal.\n\nShares of Uber and Lyft, Inc. traded lower in the premarket Monday after a California court ruled that Prop 22, a ballot measure that exempted gig workers from state labor law, was unconstitutional.\nUber was down more than 3.2% in premarket trading, while Lyft dipped nearly 3.4%.\nAlameda County Superior Court Judge Frank Roesch wrote in a ruling late Friday that Proposition 22 is unconstitutional as “it limits the power of a future Legislature to define app-based drivers as workers subject to workers’ compensation law.” That makes the entire ballot measure “unenforceable.”\nCalifornia voters approved Proposition 22 by a majority vote in November. The ballot measure effectively exempted several gig economy companies from the state’s recently enacted law, Assembly Bill 5, which had aimed to make their workers into full-time employees.\nProp 22 proposed workers for app-based food delivery and ridesharing companies should remain contractors, and be entitled to certain benefits and protections, like minimum earnings.\nThe move is a blow to gig economy companies, including Lyft, Uber, Instacart and DoorDash, which spent more than $200 million to support the ballot in an effort to maintain their current business models. Classifying drivers as contractors allows the companies to avoid the costly benefits associated with employment, such as unemployment insurance.\nA coalition representing the companies said it plans to appeal. The firms have started to fund a measure to put a similar ballot before Massachusetts voters next year.","news_type":1},"isVote":1,"tweetType":1,"viewCount":460,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}